References
1. Furer V., Rondaan C,. Heijstek M., et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041 PMID: 31673420; PMCID: PMC6803008.
2. Curtis J.R., Johnson S.R., Anthony D.D., et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2. Arthritis Rheumatol. 2021; 73 (8): e30–45. DOI: https://doi.org/10.1002/art.41877
3. Rondaan C., Furer V., Heijstek M.W., et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5 (2): e001035. DOI: https://doi.org/10.1136/rmdopen-2019-001035 PMID: 31565247; PMCID: PMC6744079.
4. Furer V., Rondaan C., Heijstek M.W., et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. DOI: https://doi.org/10.1136/annrheumdis-2019-215882
5. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021. URL: WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.2-rus.pdf; https://apps.who.int/iris/handle/10665/342147
6. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing interim guidance. First issued 8 January 2021. Updated 15 June 2021. URL: https://apps.who.int/iris/handle/10665/341786
7. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience): interim guidance, first issued 10 February 2021, updated 21 April 2021. URL: https://apps.who.int/iris/handle/10665/341190
8. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, first issued 17 March 2021, updated 15 June 2021. URL: https://apps.who.int/iris/handle/10665/341784
9. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, 24 May 2021. URL: https://apps.who.int/iris/handle/10665/341829
10. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, 7 May 2021. URL: https://apps.who.int/iris/handle/10665/341534
11. Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm Grading of evidence. Evidence to recommendation tables 7 May 2021. URL: https://apps.who.int/iris/handle/10665/341829
12. Background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19, developed by Oxford University and AstraZeneca 1 March 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222-GRADE-ETR-2021.1.
13. Background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 24 May 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-GRADE-TR
14. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy BNT162b2mRNA COVID-19. Clinical Trial Group. N Engl J Med. 2020; 383 (27): 2603–15. DOI: https://doi.org/10.1056/NEJMoa2034577
15. CDC Vaccination Considerations for Persons with Underlying Medical Conditions. 2020. URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html (date of access January 13, 2021)
16. Priori R., Pellegrino G., Colafrancesco S., et al. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis. 2021; 80 (7): 953–4. DOI: https://doi.org/10.1136/annrheumdis-2021-220059 Epub 2021 Feb 23. PMID: 33622689.
17. Park J.K., Lee E.B., Shin K., et al. Korean College of Rheumatology Task Force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021; 36 (12): e95. DOI: https://doi.org/10.3346/jkms.2021.36.e95
18. Santosa A., Xu C., Arkachaisri T., et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021; 24 (6): 746–57. DOI: https://doi.org/10.1111/1756-185X.14107
19. Lyubavina N.A., Saltsev S.G., Menkov N.V., Tyurikova L.V., Plastinina S.S., Shonia M.L., et al. Immunological approaches to the treatment of novel coronavirus infection (review). Sovrem Tehnologii Med. 2021; 13 (3): 81–99. DOI: https://doi.org/10.17691/stm2021.13.3.09
20. Principles for COVID-19 vaccination in musculoskeletal and rheumatology for clinicians. Arthritis and Musculoskeletal Alliance (Version 7, 9 June 2021). URL: www.arma.uk.net
21. Benucci M., Infantino M., Marotto D., et al. Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives. Clin Exp Rheumatol. 2021; 39 (1): 196–202.
22. Braun-Moscovici Y., Kaplan M., Braun M., et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–21. DOI: https://doi.org/10.1136/annrheumdis-2021-220503
23. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16 (8): 2825–33. DOI: https://doi.org/10.1200/JCO.1998.16.8.2825
24. Houot R., Levy R., Cartron G., Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020; 136: 4–6. DOI: https://doi.org/10.1016/j.ejca.2020.06.017